Multiple Sclerosis Progression and Relapse Activity in Children DOI
Pietro Iaffaldano, Emilio Portaccio,

Giuseppe Lucisano

et al.

JAMA Neurology, Journal Year: 2023, Volume and Issue: 81(1), P. 50 - 50

Published: Nov. 27, 2023

Importance Although up to 20% of patients with multiple sclerosis (MS) experience onset before 18 years age, it has been suggested that people pediatric-onset MS (POMS) are protected against disability because greater capacity for repair. Objective To assess the incidence and factors associated progression independent relapse activity (PIRA) relapse-associated worsening (RAW) in POMS compared typical adult-onset (AOMS) late-onset (LOMS). Design, Setting, Participants This cohort study on prospectively acquired data from Italian Register was performed June 1, 2000, September 30, 2021. At time extraction, longitudinal 73 564 120 centers were available register. Main Outcomes Measures The main outcomes included age-related cumulative adjusted hazard ratios (HRs) PIRA RAW factors. Exposures Clinical magnetic resonance imaging features, receiving disease-modifying therapy (DMT), first DMT. Results After applying inclusion exclusion criteria, assessed 16 130 (median [IQR] age at onset, 28.7 [22.8-36.2 years]; 68.3% female). Compared AOMS LOMS, had less disability, exhibited more active disease, exposed DMT a longer period. A 48-week-confirmed occurred 7176 (44.5%): 558 (40.4%), 6258 (44.3%), 360 LOMS (56.8%) ( P < .001). Factors older (AOMS vs HR, 1.42; 95% CI, 1.30-1.55; 2.98; 2.60-3.41; .001), disease duration (HR, 1.04; 1.04-1.05; shorter exposure 0.69; 0.64-0.74; 1.3% 20 but rapidly increased approximately 7 times between 21 30 (9.0%) nearly doubled each decade 40 70 (21.6% years, 39.0% 50 61.0% 60 78.7% years). events followed similar trend (0.5% 3.5% 7.8% 14.4% 24.1% years); no further increase found (27.7%). Delayed initiation higher risk 1.16; 1.00-1.34; = .04) 1.75; 1.28-2.39; Conclusions Relevance can occur any although pediatric is not fully protective progression, this study’s findings suggest likely exhibit over follow-up. However, these also reinforce benefit POMS, as treatment reduced occurrence both regardless onset.

Language: Английский

Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study DOI
Romain Marignier, Javier Villacieros‐Álvarez, Carmen Espejo

et al.

Journal of Neurology Neurosurgery & Psychiatry, Journal Year: 2025, Volume and Issue: unknown, P. jnnp - 335137

Published: Feb. 12, 2025

Background Serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) have emerged as important biomarkers in multiple sclerosis (MS) aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD). However, their interest myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) remains unclear. Our aim was to characterise sNfL sGFAP profile analyse usefulness predicting relapses disability MOGAD. Methods Retrospective study of adult MOGAD patients with samples collected at baseline (≤3 months from onset) follow-up (>6 sample). were analysed using Simoa HD-1, values compared across time-points. The association between clinical variables predictive value for analysed. Results Eighty-nine included. Baseline high decreased over time (p<0.001, p=0.027, respectively). associated Expanded Disability Status Scale (EDSS) attacks (β 0.15 (0.06; 0.25), p=0.002; β 0.14 (0.07; 0.21), p<0.001, respectively) lower optic neuritis presentations −0.69 (−1.18; −0.19), p=0.007; −0.42 (−0.76; −0.08), p=0.016). Biomarker deltas[Δ] (baseline – second values) ΔEDSS (initial EDSS - final EDSS) (ΔsNfL 0.52 (0.01; 1.04), p=0.046; ΔsGFAP 1.07 (0.38; 1.75), p=0.003). Finally, independently predicted the risk (HR 2.06 (1.41; 3.01), p<0.001). Conclusions results on suggest initial neuro-axonal astrocytic damage utility these onset recovery relapses.

Language: Английский

Citations

1
A comprehensive review of the advances in neuromyelitis optica spectrum disorder DOI Creative Commons
Pakeeran Siriratnam, Saif Huda, Helmut Butzkueven

et al.

Autoimmunity Reviews, Journal Year: 2023, Volume and Issue: 22(12), P. 103465 - 103465

Published: Oct. 16, 2023

Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing neuroinflammatory autoimmune astrocytopathy, with predilection for the optic nerves and spinal cord. Most cases are characterised by aquaporin-4-antibody positivity have disease course, which associated accrual of disability. Although prognosis in NMOSD has improved markedly over past few years owing to advances diagnosis therapeutics, it remains severe disease. In this article, we review evolution our understanding NMOSD, its pathogenesis, clinical features, treatment options symptoms. We also address gaps knowledge areas future research focus.

Language: Английский

Citations

22
Building a monitoring matrix for the management of multiple sclerosis DOI
Isabel Voigt, Hernán Inojosa, Judith Wenk

et al.

Autoimmunity Reviews, Journal Year: 2023, Volume and Issue: 22(8), P. 103358 - 103358

Published: May 12, 2023

Language: Английский

Citations

19
Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches DOI
Eleni S. Vasileiou, Kathryn C. Fitzgerald

Current Allergy and Asthma Reports, Journal Year: 2023, Volume and Issue: 23(9), P. 481 - 496

Published: July 4, 2023

Language: Английский

Citations

19
Multiple Sclerosis Progression and Relapse Activity in Children DOI
Pietro Iaffaldano, Emilio Portaccio,

Giuseppe Lucisano

et al.

JAMA Neurology, Journal Year: 2023, Volume and Issue: 81(1), P. 50 - 50

Published: Nov. 27, 2023

Importance Although up to 20% of patients with multiple sclerosis (MS) experience onset before 18 years age, it has been suggested that people pediatric-onset MS (POMS) are protected against disability because greater capacity for repair. Objective To assess the incidence and factors associated progression independent relapse activity (PIRA) relapse-associated worsening (RAW) in POMS compared typical adult-onset (AOMS) late-onset (LOMS). Design, Setting, Participants This cohort study on prospectively acquired data from Italian Register was performed June 1, 2000, September 30, 2021. At time extraction, longitudinal 73 564 120 centers were available register. Main Outcomes Measures The main outcomes included age-related cumulative adjusted hazard ratios (HRs) PIRA RAW factors. Exposures Clinical magnetic resonance imaging features, receiving disease-modifying therapy (DMT), first DMT. Results After applying inclusion exclusion criteria, assessed 16 130 (median [IQR] age at onset, 28.7 [22.8-36.2 years]; 68.3% female). Compared AOMS LOMS, had less disability, exhibited more active disease, exposed DMT a longer period. A 48-week-confirmed occurred 7176 (44.5%): 558 (40.4%), 6258 (44.3%), 360 LOMS (56.8%) ( P &amp;lt; .001). Factors older (AOMS vs HR, 1.42; 95% CI, 1.30-1.55; 2.98; 2.60-3.41; .001), disease duration (HR, 1.04; 1.04-1.05; shorter exposure 0.69; 0.64-0.74; 1.3% 20 but rapidly increased approximately 7 times between 21 30 (9.0%) nearly doubled each decade 40 70 (21.6% years, 39.0% 50 61.0% 60 78.7% years). events followed similar trend (0.5% 3.5% 7.8% 14.4% 24.1% years); no further increase found (27.7%). Delayed initiation higher risk 1.16; 1.00-1.34; = .04) 1.75; 1.28-2.39; Conclusions Relevance can occur any although pediatric is not fully protective progression, this study’s findings suggest likely exhibit over follow-up. However, these also reinforce benefit POMS, as treatment reduced occurrence both regardless onset.

Language: Английский

Citations

17